CRBP Corbus Pharmaceuticals Holdings, Inc.
Data as of close
Healthcare · Pharmaceutical Preparations
Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $55 million. Shares last traded at $2.84, 77.7% below their 52-week high. Over the past year the stock is down 74.8%. Revenue declined 100.0% year over year.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | -$1.81 | 2026-08-06 |
| Q1 2026 | -$1.23 | 2026-05-12 |
| Q4 2025 (derived) | -$1.17 | 2026-03-09 |
| FY 2025 | -$5.90 | 2026-03-09 |
| Q3 2025 | -$1.90 | 2025-11-12 |
| Q2 2025 | -$1.44 | 2025-08-05 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Pharmaceutical Preparations peers
CRBP vs 14 industry peers (Pharmaceutical Preparations), by market cap. Data as of close
| LLY | Lilly (Eli) | $1.29T | 46.64 | 14.88 | 31.9% | -3.58% |
| JNJ | Johnson & Johnson | $655.6B | 40.73 | 6.60 | 16.2% | -1.45% |
| ONC | Beone Medicines Ltd. | $575.1B | 628.16 | 87.05 | 13.9% | +2.60% |
| ABBV | AbbVie | $509.5B | 49.26 | 7.72 | 15.7% | -2.26% |
| MRK | Merck | $362.1B | 147.62 | 5.37 | 3.6% | -2.31% |
| ABT | Abbott Laboratories | $196.7B | 41.83 | 4.08 | 9.7% | -1.75% |
| PFE | Pfizer | $170.3B | 42.23 | 2.68 | 6.3% | -2.96% |
| VRTX | Vertex Pharmaceuticals | $137.6B | 34.61 | 10.62 | 30.7% | -1.15% |
| BMY | Bristol Myers Squibb | $129.1B | 13.96 | 2.58 | 18.5% | -1.65% |
| REGN | Regeneron Pharmaceuticals | $93.4B | 19.39 | 5.53 | 28.5% | -3.01% |
| TEVA | Teva Pharmaceutical Industries Ltd | $48.7B | 96.32 | 2.83 | 2.9% | -0.07% |
| ZTS | Zoetis | $33.4B | 13.43 | 3.51 | 26.1% | -7.86% |
| RPRX | Royalty Pharma Plc | $30.1B | 44.79 | 11.49 | 25.7% | -0.03% |
| ROIV | Roivant Sciences Ltd. | $26.5B | — | 3512.84 | — | -4.16% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.